Scott T Avecilla
Overview
Explore the profile of Scott T Avecilla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wheeler A, Snyder E, Refaai M, Cohn C, Poisson J, Fontaine M, et al.
Blood Adv
. 2024 Mar;
8(9):2290-2299.
PMID: 38447116
Patients treated with antineoplastic therapy often develop thrombocytopenia requiring platelet transfusion, which has potential to exacerbate pulmonary injury. This study tested the hypothesis that amotosalen-UVA pathogen-reduced platelet components (PRPCs) do...
2.
Cho C, Hilden P, Avecilla S, Barker J, Castro-Malaspina H, Giralt S, et al.
Adv Cell Gene Ther
. 2022 Nov;
4(1).
PMID: 36339371
Objective: To determine outcomes based on both disease- and patient-specific factors, we evaluated a prognostic model combining the Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), an...
3.
Snyder E, Wheeler A, Refaai M, Cohn C, Poisson J, Fontaine M, et al.
Transfusion
. 2022 Jun;
62(7):1365-1376.
PMID: 35748490
Background: Platelet transfusion carries risk of transfusion-transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including transfusion-related acute lung injury and...
4.
Lakkaraja M, Scordo M, Mauguen A, Cho C, Devlin S, Ruiz J, et al.
Blood Adv
. 2021 Nov;
6(3):1054-1063.
PMID: 34788361
Traditional weight-based dosing results in variable rabbit antithymocyte globulin (rATG) clearance that can delay CD4+ T-cell immune reconstitution (CD4+ IR) leading to higher mortality. In a retrospective pharmacokinetic/pharmacodynamic (PK/PD) analysis...
5.
Shouval R, Fein J, Cho C, Avecilla S, Ruiz J, Tomas A, et al.
Blood Adv
. 2021 Sep;
6(5):1525-1535.
PMID: 34507354
Individual comorbidities have distinct contributions to nonrelapse mortality (NRM) following allogeneic hematopoietic cell transplantation (allo-HCT). We studied the impact of comorbidities individually and in combination in a single-center cohort of...
6.
Avecilla S, Boulad F, Yazdanbakhsh K, Sadelain M, Shi P
Transfusion
. 2021 Jun;
61(9):2775-2781.
PMID: 34160085
Background: Adequate CD34+ collection efficiency (CE) is critical to achieve target CD34+ cell doses in hematopoietic progenitor cell (HPC) collections. Autologous HPC collection in sickle cell disease (SCD) is associated...
7.
Jacob R, Flynn J, Devlin S, Maloy M, Giralt S, Maslak P, et al.
Transplant Cell Ther
. 2021 May;
27(8):697.e1-697.e5.
PMID: 33991721
As a result of the COVID-19 pandemic, most centers performing allogeneic hematopoietic cell transplantation (allo-HCT) have switched to the use of cryopreserved grafts. Previous investigators have suggested that cryopreserved allografts...
8.
Jacob R, Walsh E, Maslak P, Giralt S, Avecilla S
Transfusion
. 2021 Mar;
61(5):1525-1532.
PMID: 33694175
Background: Hematopoietic stem cell transplantation is an important treatment that is dependent on the collection of sufficient CD34+ hematopoietic progenitor cells. The peripheral blood CD34 count (PB CD34+ counts) measured...
9.
Barker J, Devlin S, Naputo K, Skinner K, Maloy M, Flynn L, et al.
Blood Adv
. 2020 Dec;
4(23):6064-6076.
PMID: 33290545
Cord blood transplantation (CBT) after high intensity or nonmyeloablative conditioning has limitations. We investigated cyclosporine-A/mycophenolate mofetil-based intermediate intensity (cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg, total body irradiation...
10.
Stone E, Avecilla S, Wuest D, Lomas-Francis C, Westhoff C, Diuguid D, et al.
Haematologica
. 2020 Aug;
106(1):310-312.
PMID: 32817291
No abstract available.